A raised full-year sales forecast plus strong demand for GLP-1 therapies and an earnings beat are near-term fundamental positives likely to drive follow-through beyond the day’s move.
Eli Lilly stock soars on strong demand for weight loss drugs Yahoo Finance Wed, August 5, 2026 at 3:53 PM GMT+2 1 min read LLY What happened: Eli Lilly ( LLY ) stock jumped as much as 7% on Wednesday. What's behind the move: The drug company raised its 2026 sales forecast after it saw strong demand for GLP-1 drugs in its fiscal second quarter. Revenue is now expected to fall between $85 billion and $87 billion for the year, topping an earlier forecast of up to $85 billion, according to Bloomberg data.
Adjusted earnings for the second quarter also beat Wall Street estimates. This embedded content is not available in your region. What else you need to know: Eli Lilly's GLP-1 business has been the growth engine of the drug company, benefiting from several tailwinds since the start of the year, including the FDA's approval of Foundayo, the pill version of its weight-loss drug, earlier this year.
The company is also developing next-generation weight-loss medicine retatrutide. It has clinical data in hand and plans to file for FDA approval in the first quarter of next year. Shares of the drugmaker have rebounded from a first-quarter slump, with the stock climbing more than 40% since the end of April and gaining 3% year to date, according to Yahoo Finance's AlphaSpace data.
Ines is a markets reporter covering equities.
Oraklio AI Trading Intelligence
Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.
Get started freeAlready have an account? Sign in →